Viruses for tumor therapy

Cell Host and Microbe

Volumn 15, Issue 3, 2014, Pages 260-265

  Bell, John ^a   McFadden, Grant ^b  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAVATAK; CG 0070; CGTG 102; COLO AD1; DNX 2401; G 207; GL ONC1; H 1 PV; H101; HF10; ICOVIR 5; ONCOLYTIC VIRUS; PELAREOREP; PEXASTIMOGENE DEVACIREPVEC; PVS RIPO; SEPREHVIR; TALIMOGENE LAHERPAREPVEC; UNCLASSIFIED DRUG;

ADENOVIRUS; ANTINEOPLASTIC ACTIVITY; BLADDER CANCER; BRAIN TUMOR; BREAST CANCER; CANCER THERAPY; COLON CANCER; COLORECTAL CANCER; GLIOBLASTOMA; H-1 PARVOVIRUS; HEAD AND NECK CANCER; HERPES VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; LIVER CANCER; LIVER CELL CARCINOMA; LUNG CANCER; MARABA VIRUS; MEASLES VIRUS; MELANOMA; MYELOMA; NEOPLASM; NEUROBLASTOMA; NEUROENDOCRINE TUMOR; NEWCASTLE DISEASE PARAMYXOVIRUS; ONCOLYTIC VIROTHERAPY; OVARY CANCER; PANCREAS CANCER; PARAMYXOVIRUS; PERITONEUM CANCER; PICORNAVIRUS; POXVIRUS; PRIORITY JOURNAL; REOVIRUS; RHABDOVIRUS; SHORT SURVEY; SKIN CANCER; SOLID TUMOR; TREATMENT FAILURE; TROPISM; VESICULAR SOMATITIS VIRUS;

CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; IMMUNOLOGIC FACTORS; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; TREATMENT OUTCOME; VIRAL TROPISM;

EID: 84896087235     PISSN: 19313128     EISSN: 19346069     Source Type: Journal    
DOI: 10.1016/j.chom.2014.01.002     Document Type: Review

References (29)

1. Adair, R.A., Roulstone, V., Scott, K.J., Morgan, R., Nuovo, G.J., Fuller, M., Beirne, D., West, E.J., Jennings, V.A., Rose, A., Kyula, J., Fraser, S., Dave, R., Anthoney, D.A., Merrick, A., Prestwich, R., Aldouri, A., Donnelly, O., Pandha, H., Coffey, M., Selby, P., Vile, R., Toogood, G., Harrington, K., and Melcher, A.A. (2012). Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients. Sci. Trans. Med. 4, http://dx.doi.org/10. 1126/scitranslmed.3003578.
2. Bartlett, D.L., Liu, Z., Sathaiah, M., Ravindranathan, R., Guo, Z., He, Y., and Guo, Z.S. (2013). Oncolytic viruses as therapeutic cancer vaccines. Mol. Cancer 12, 103-119.
3. Bourke, M.G., Salwa, S., Harrington, K.J., Kucharczyk, M.J., Forde, P.F., de Kruijf, M., Soden, D., Tangney, M., Collins, J.K., and O'Sullivan, G.C. (2011). The emerging role of viruses in the treatment of solid tumours. Cancer Treat. Rev. 37, 618-632.
4. Breitbach, C.J., Burke, J., Jonker, D., Stephenson, J., Haas, A.R., Chow, L.Q., Nieva, J., Hwang, T.H., Moon, A., Patt, R., et al. (2011). Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 477, 99-102.
5. Breitbach, C.J., Arulanandam, R., De Silva, N., Thorne, S.H., Patt, R., Daneshmand, M., Moon, A., Ilkow, C., Burke, J., Hwang, T.H., et al. (2013). Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans. Cancer Res. 73, 1265-1275.
6. Donnelly, O.G., Errington-Mais, F., Prestwich, R., Harrington, K., Pandha, H., Vile, R., and Melcher, A.A. (2012). Recent clinical experience with oncolytic viruses. Curr. Pharm. Biotechnol. 13, 1834-1841.
7. Donnelly, O., Harrington, K., Melcher, A., and Pandha, H. (2013). Live viruses to treat cancer. J. R. Soc. Med. 106, 310-314.
8. Eager, R.M., and Nemunaitis, J. (2011). Clinical development directions in oncolytic viral therapy. Cancer Gene Ther. 18, 305-317.
9. Elsedawy, N.B., and Russell, S.J. (2013). Oncolytic vaccines. Expert Rev. Vaccines 12, 1155-1172.
10. Frebel, H., and Oxenius, A. (2013). The risks of targeting co-inhibitory pathways to modulate pathogen-directed T cell responses. Trends Immunol. 34, 193-199.
11. Gao, J., Bernatchez, C., Sharma, P., Radvanyi, L.G., and Hwu, P. (2013). Advances in the development of cancer immunotherapies. Trends Immunol. 34, 90-98.
12. Hayden, E.C. (2008). Cancer complexity slows quest for cure. Nature 455, 148.
13. Heo, J., Reid, T., Ruo, L., Breitbach, C.J., Rose, S., Bloomston, M., Cho, M., Lim, H.Y., Chung, H.C., Lim, W.C., Burke, J., Lencioni, R., Hickman, T., Moon, A., Lee, Y.S., Kim, M.K., Daneshmand, M., Dubois, K., Longpre, L., Ngo, M., Rooney, C., Bell, J.C., Rhee, B., Patt, R., Hwang, T., and Kirn, D.H. (2013). Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat. Med. 19, 329-336.
14. Kelly, E., and Russell, S.J. (2007). History of oncolytic viruses: genesis to genetic engineering. Mol. Ther. 15, 651-659. (Pubitemid 46431984)
15. Mader, E.K., Butler, G., Dowdy, S.C., Mariani, A., Knutson, K.L., Federspiel, M.J., Russell, S.J., Galanis, E., Dietz, A.B., and Peng, K.W. (2013). Optimizing patient derived mesenchymal stem cells as virus carriers for a phase I clinical trial in ovarian cancer. J. Transl. Med. 11, 20-34.
16. Melcher, A., Parato, K., Rooney, C.M., and Bell, J.C. (2011). Thunder and lightning: immunotherapy and oncolytic viruses collide. Mol. Ther. 19, 1008-1016.
17. Miest, T.S., and Cattaneo, R. (2014). New viruses for cancer therapy: meeting clinical needs. Nat. Rev. Microbiol. 12, 23-34.
18. Naik, S., Nace, R., Federspiel, M.J., Barber, G.N., Peng, K.W., and Russell, S.J. (2012). Curative one-shot systemic virotherapy in murine myeloma. Leukemia 26, 1870-1878.
19. Ottolino-Perry, K., Diallo, J.S., Lichty, B.D., Bell, J.C., and McCart, J.A. (2010). Intelligent design: combination therapy with oncolytic viruses. Mol. Ther. 18, 251-263.
20. Patel, M.R., and Kratzke, R.A. (2013). Oncolytic virus therapy for cancer: the first wave of translational clinical trials. Transl. Res. 161, 355-364.
21. Rahman, M.M., Madlambayan, G.J., Cogle, C.R., and McFadden, G. (2010). Oncolytic viral purging of leukemic hematopoietic stem and progenitor cells with Myxoma virus. Cytokine Growth Factor Rev. 21, 169-175.
22. Ribas, A., and Wolchok, J.D. (2013). Combining cancer immunotherapy and targeted therapy. Curr. Opin. Immunol. 25, 291-296.
23. Russell, S.J., Peng, K.W., and Bell, J.C. (2012). Oncolytic virotherapy. Nat. Biotechnol. 30, 658-670.
24. Sze, D.Y., Reid, T.R., and Rose, S.C. (2013). Oncolytic virotherapy. J. Vasc. Interv. Radiol. 24, 1115-1122.
25. Tong, A.W., Senzer, N., Cerullo, V., Templeton, N.S., Hemminki, A., and Nemunaitis, J. (2012). Oncolytic viruses for induction of anti-tumor immunity. Curr. Pharm. Biotechnol. 13, 1750-1760.
26. Vacchelli, E., Eggermont, A., Sautès-Fridman, C., Galon, J., Zitvogel, L., Kroemer, G., and Galluzzi, L. (2013). Trial watch: Oncolytic viruses for cancer therapy. OncoImmunology 2, e24612.
27. Vanneman, M., and Dranoff, G. (2012). Combining immunotherapy and targeted therapies in cancer treatment. Nat. Rev. Cancer 12, 237-251.
28. Wennier, S.T., Liu, J., and McFadden, G. (2012). Bugs and drugs: oncolytic virotherapy in combination with chemotherapy. Curr. Pharm. Biotechnol. 13, 1817-1833.
29. Willmon, C., Harrington, K., Kottke, T., Prestwich, R., Melcher, A., and Vile, R. (2009). Cell carriers for oncolytic viruses: Fed Ex for cancer therapy. Mol. Ther. 17, 1667-1676.